- Home
- SGLY vs GLTO Comparison
SGLY vs GLTO Comparison
Compare SGLY & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- GLTO
- Stock Information
- Founded
- SGLY 2001
- GLTO 2011
- Country
- SGLY United States
- GLTO Denmark
- Employees
- SGLY N/A
- GLTO N/A
- Industry
- SGLY
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- GLTO Health Care
- Exchange
- SGLY Nasdaq
- GLTO Nasdaq
- Market Cap
- SGLY 5.8M
- GLTO 6.5M
- IPO Year
- SGLY 2008
- GLTO 2020
- Fundamental
- Price
- SGLY $2.60
- GLTO $5.30
- Analyst Decision
- SGLY
- GLTO Buy
- Analyst Count
- SGLY 0
- GLTO 1
- Target Price
- SGLY N/A
- GLTO $10.00
- AVG Volume (30 Days)
- SGLY 115.1K
- GLTO 21.2K
- Earning Date
- SGLY 02-26-2025
- GLTO 03-07-2025
- Dividend Yield
- SGLY N/A
- GLTO N/A
- EPS Growth
- SGLY N/A
- GLTO N/A
- EPS
- SGLY N/A
- GLTO N/A
- Revenue
- SGLY $2,742,157.00
- GLTO N/A
- Revenue This Year
- SGLY N/A
- GLTO N/A
- Revenue Next Year
- SGLY N/A
- GLTO N/A
- P/E Ratio
- SGLY N/A
- GLTO N/A
- Revenue Growth
- SGLY N/A
- GLTO N/A
- 52 Week Low
- SGLY $1.27
- GLTO $4.40
- 52 Week High
- SGLY $7.65
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- SGLY 57.89
- GLTO 52.98
- Support Level
- SGLY $1.98
- GLTO $4.60
- Resistance Level
- SGLY $5.49
- GLTO $5.85
- Average True Range (ATR)
- SGLY 0.57
- GLTO 0.41
- MACD
- SGLY 0.12
- GLTO 0.09
- Stochastic Oscillator
- SGLY 29.20
- GLTO 65.21
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.